Ross L. Levine, MD
Genomic characterizations of myeloproliferative neoplasms
The Levine Lab studies chronic leukemias which manifest as an excess of red blood cells, platelets, and white blood cells, respectively. Importantly, these patients are at high risk for developing bone marrow failure (due to increased scar tissue in their bone marrow) or transformation to acute leukemia; when patients develop these complications there are no curative treatments. The goal of this proposal is therefore to use state-of-the-art genomic technologies in order to identify additional mutations in leukemia patients and to develop novel, molecularly targeted therapies. The long-term goal of their research efforts are thus to use genetic insights in order to improve outcomes and reduce toxicities for all patients with these chronic leukemias.